Please assess the completion status of the following clinical trial:

Trial Title: TSO in Pediatric Autistic Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, ages 6 to 17 years, inclusive~2. Diagnosis via Diagnostic and Statistical Manual for Mental Disorders- Forth Edition (DSM-IV)-and confirmed by Autism Diagnostic Observation~   Schedule (ADOSI):~3. CGI-Severity score \> 4 and ABC irritability score \> 18~4. Mental age of \> 18 months~5. Weight of at least \*\* kg~6. Currently psychotropic medication free or on stable dose of psychotropic medication for at least 3 months prior to the study.~7. Willing to comply with the schedule of study visits and protocol requirements~8. Patient and/or guardian have the ability to provide informed consent~Exclusion Criteria:~1. Previous diagnosis of Rett's Disorder, Aspergers Disorder, Childhood Disintegrative Disorder, Fragile X Syndrome, or other disorders on the autism spectrum~2. History of Bipolar Disorder, Psychotic Disorders, or major Depression~3. Seizure within the previous 6 months~4. Patient received antibiotic, antifungal or antiparasitic medication in the last 2 weeks prior to Screening and/or would potentially require this during the study treatment period~5. Patient with history of drug or alcohol abuse within 6 months prior to Screening~6. Patient with evidence of poor compliance with medical advice and instruction including diet or medication~7. Patient is unable or unwilling to swallow study medication suspension~8. Patient with a significant medical condition which puts the patient at risk for study participation and/or for any reason is considered by the Investigator to be an unsuitable candidate to receive TSO or is potentially put at risk by study procedures~9. Patient who has participated in another clinical trial within 30 days of Screening for this trial and/or any experimental treatment for this population~10. Females of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period~11. Females who are pregnant or breastfeeding at the time of enrollment~12. Patients with any of the following laboratory values:~    1. White blood cell count ≤ 3,000/mm3 (≤ 3.0 x 109/L) or ≥ 14,000/mm3 (≥14 x 109/L)~   2. Platelet count ≤ 100,000/μL (≤100 x 109/L)~   3. Serum creatinine ≥ 1.5 mg/dL (≥ 132.6 μmol/L) or \>2 x upper limit of normal (ULN)~   4. AST (SGOT) or ALT (SGPT) \> 2 x ULN~   5. Total bilirubin \>2 mg/dL (34 μmol/L)~   6. Hemoglobin \< 9 g/dL

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- TSO 2500 (Type: ACTIVE_COMPARATOR): 2500 TSO every other week
- 7500 TSO (Type: ACTIVE_COMPARATOR): 7500 TSO every other week
- Placebo (Type: PLACEBO_COMPARATOR): placebo every other week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy